CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025

EQS-News: PharmaSGP Holding SE / Key word(s): Personnel CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025 05.11.2024 / 10:07 CET/CEST The issuer is solely responsible for the content of this announcement. CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025

 

Gräfelfing, November 05, 2024 - German OTC pharmaceutical company PharmaSGP Holding SE is announcing a change in the position of Chief Executive Officer (CEO). After more than seven years as CEO, Natalie Weigand informed the Supervisory Board today that, due to personal reasons, she will not be renewing her contract with PharmaSGP, which expires at the end of the year. Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will succeed Ms. Weigand as CEO on January 1, 2025. Peter Gerckens has already been able to familiarize himself extensively with PharmaSGP since July 2024 and will continue to drive PharmaSGP's successful growth course as CEO. The internal succession plan ensures a smooth and rapid transition process. In addition, there is continuity in the PharmaSGP Management Board team with Michael Rudolf as longstanding Chief Financial Officer (CFO). Natalie Weigand will also remain active for the company in an advisory position.

Natalie Weigand, CEO of PharmaSGP, on her upcoming exit: "After careful consideration, I have decided not to extend my contract with PharmaSGP after almost ten years with the company, including more than seven years as CEO. I would like to thank all my colleagues for the successful time we shared and wish each and every one of them all the best. I will remain associated with the company in an advisory position in the future and look forward to accompanying the ongoing success story of PharmaSGP from this new perspective."

Dr. Clemens Fischer, Chairman of the Supervisory Board: "On behalf of the entire Supervisory Board and the entire company, we would like to thank Ms. Weigand for her outstanding contribution to the successful development of PharmaSGP in recent years. Under her leadership, PharmaSGP has regularly achieved new revenue and earnings records. We wish Ms. Weigand all the best for the future and are delighted that she will continue to support the company in an advisory role. At the same time, we are very happy that we have been able to find an internal successor in Peter Gerckens. Mr. Gerckens knows the business model, the market and the growth opportunities inside out and is therefore, in our view, the ideal person to successfully lead PharmaSGP in the future."